GSK’s Jemperli (dostarlimab) won accelerated FDA approval for advanced rectal cancer patients with a specific genetic signature, expanding the checkpoint inhibitor’s label beyond its prior endometrial-cancer indication. The move is positioned as an additional surgery-sparing option as checkpoint therapy use broadens across colorectal treatment settings.